Leerink Partnrs Issues Optimistic Forecast for TNDM Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) - Leerink Partnrs lifted their FY2028 earnings per share (EPS) estimates for Tandem Diabetes Care in a research note issued to investors on Wednesday, April 30th. Leerink Partnrs analyst M. Kratky now forecasts that the medical device company will post earnings of $0.42 per share for the year, up from their previous estimate of $0.31. The consensus estimate for Tandem Diabetes Care's current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care's FY2029 earnings at $0.88 EPS.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The company had revenue of $234.42 million for the quarter, compared to analysts' expectations of $220.19 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The company's revenue for the quarter was up 22.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.65) EPS.

TNDM has been the subject of several other research reports. The Goldman Sachs Group cut their price objective on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Robert W. Baird decreased their price target on Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating for the company in a research note on Thursday. Citigroup downgraded Tandem Diabetes Care from a "buy" rating to a "neutral" rating and cut their price target for the company from $35.00 to $24.00 in a report on Tuesday, March 4th. Stifel Nicolaus lowered their price target on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating for the company in a report on Thursday. Finally, Royal Bank of Canada lowered their price target on Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating for the company in a research report on Thursday, February 27th. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, Tandem Diabetes Care has an average rating of "Moderate Buy" and a consensus target price of $39.81.

Tandem Diabetes Care Stock Up 18.6 %

Shares of Tandem Diabetes Care stock opened at $19.98 on Friday. Tandem Diabetes Care has a 12-month low of $15.75 and a 12-month high of $53.69. The company's fifty day simple moving average is $19.04 and its two-hundred day simple moving average is $28.75. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The company has a market cap of $1.33 billion, a P/E ratio of -10.35 and a beta of 1.52.

Institutional Trading of Tandem Diabetes Care

Hedge funds and other institutional investors have recently made changes to their positions in the company. Arizona State Retirement System grew its stake in shares of Tandem Diabetes Care by 1.9% during the 4th quarter. Arizona State Retirement System now owns 18,961 shares of the medical device company's stock worth $683,000 after purchasing an additional 362 shares during the period. Bank of Montreal Can grew its position in Tandem Diabetes Care by 4.3% during the fourth quarter. Bank of Montreal Can now owns 10,004 shares of the medical device company's stock worth $360,000 after buying an additional 409 shares during the period. Summit Investment Advisors Inc. increased its holdings in Tandem Diabetes Care by 8.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,870 shares of the medical device company's stock valued at $247,000 after buying an additional 525 shares in the last quarter. Assetmark Inc. lifted its position in shares of Tandem Diabetes Care by 77.5% during the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after acquiring an additional 535 shares during the period. Finally, AlphaQuest LLC boosted its stake in shares of Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after acquiring an additional 541 shares in the last quarter.

Insider Activity

In related news, COO Jean-Claude Kyrillos acquired 10,538 shares of Tandem Diabetes Care stock in a transaction on Friday, March 7th. The stock was purchased at an average cost of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.90% of the company's stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.